<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210249</url>
  </required_header>
  <id_info>
    <org_study_id>IB2002-26</org_study_id>
    <secondary_id>ONCOGERIATRIE</secondary_id>
    <nct_id>NCT00210249</nct_id>
  </id_info>
  <brief_title>Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment</brief_title>
  <acronym>ONCOGERIATRIE</acronym>
  <official_title>Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chugai Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <brief_summary>
    <textblock>
      Number of elderly people over 70 is increasing in France. In 2002, in the south-west, 273,741
      of them were over 75 years, i.e. 9.2% of Aquitaine population. Incidence of cancer in this
      old age is 16,500 new cases per year, more than fifty percent of people with cancer.
      Treatment modalities of elderly people is one of the 70 priorities of the &quot;Plan cancer&quot;
      instituted by the French government. They are very few therapeutic trials dedicated.
      Oncologists hesitate to treat them because they are either afraid of inducing toxicity or of
      breaking down quality of life. Consequently, we decided to launch a protocol with both
      oncologists and geriatricians which principal aim is to find out if geriatric assessment data
      can help to better predict for chemotherapy toxicity, loss of autonomy and survival. We plan
      to accrue 360 patients diagnosed for cancer, including digestive, pulmonary, prostate,
      lymphoma, bladder, ovary cancer for whom first-line chemotherapy is planned. Patients are
      initially classified according to usual methods of medical oncology practice into three
      groups: patients who can receive standard treatment, reduced standard treatment or treatment
      adapted to the frail condition. Around Aquitaine, , we organised seven teams composed of one
      geriatrician and one nurse. Two kind of teams were activated: one which cover ten treatment
      sites in Bordeaux area and six sedentary teams which worked half a day a week in designated
      hospitals . Geriatric evaluation included test of cognitive functions (MMS), nutritional
      status (MNA), co-morbidity (CIRS-G), mobility (Get up and Go), activities (ADL;IADL), quality
      of life (QLQ-C30), depression (GDS-15) and Lachs-Balducci screening. Patients have four
      geriatric evaluations : before treatment, day 1 cycle 2, day 1 cycle 4, day 1 cycle 7 and/or
      end of chemotherapy. Since September 2002, 177 patients have been included, 112 have
      finished: 47.3% have received four evaluations, 16.1% died before the end of protocol, 14.3%
      stopped because they were in progression and changed their treatment, 11.6% met
      administrative problem that didn't allow all evaluations, 7.1% declined after inclusion and
      3.6% finished their treatment before. The following results have been obtained: before
      treatment, 73% of these patients were at risk of undernutrition (MNA&lt; 23.5), about 1/3 had
      one or more inability or a risk of falls (38% IADL&lt;6, 29% get up and go&gt;20seconds, 27% ADL&gt;1,
      34% PS&lt;1), 28% of them had altered cognitive functions (MMS&lt;24), 29% were depressive
      (GDS-15&gt;6), 25% thought they had poor quality of life (QLQ-C30&lt;4). Protocol will be closed in
      September 2005.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2002</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Actual">360</enrollment>
  <condition>Lymphoma</condition>
  <condition>Digestive System Diseases</condition>
  <condition>Ovarian Diseases</condition>
  <condition>Pulmonary Disease</condition>
  <condition>Prostatic Disease</condition>
  <condition>Bladder Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        -  cancer du colon en indication de chimiothérapie (adjuvante ou palliative) ;

          -  cancer de l'estomac en indication de chimiothérapie (d'induction ou palliative) ;

          -  Cancer du pancréas en indication de chimiothérapie

          -  cancer de l'ovaire en indication de chimiothérapie (adjuvante ou palliative) ;

          -  tous lymphomes diffus à grandes cellules B, tous lymphomes T périphériques (la
             majorité de ces patients seront a priori inclus dans les essais 20991 et 20992 de
             l'EORTC) ;

          -  tous lymphomes de faible malignité : lymphocytiques, lympho-plasmocytaires,
             folliculaires, manteau, zone marginale (MALT et autres).

          -  Cancer de la prostate en indication de chimiothérapie

          -  Cancer de la vessie en indication de chimiothérapie

          -  Cancer bronchique en indication de chimiothérapie

          -  Adénocarcinome de primitif inconnu compatible avec une origine citée ci-dessus en
             indication de chimiothérapie
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥ 70 years

          -  First line of chemotherapy

          -  Cancer previously mentioned
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre SOUBEYRAN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de radiothérapie d'Agen</name>
      <address>
        <city>Agen</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire d'Agen</name>
      <address>
        <city>Agen</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Esquirol Saint Hilaire</name>
      <address>
        <city>Agen</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bayonne</name>
      <address>
        <city>Bayonne</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de la Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Etienne du Pays Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Tivoli</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Dax</name>
      <address>
        <city>Dax</city>
        <zip>40100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sub-Urbain du Bouscat</name>
      <address>
        <city>Le Bouscat</city>
        <zip>33110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Mont de Marsan</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Perigueux</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maison de Santé Protestante Bagatelle</name>
      <address>
        <city>Talence</city>
        <zip>33400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Villeneuve sur Lot</name>
      <address>
        <city>Villeneuve sur Lot</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>July 25, 2013</last_update_submitted>
  <last_update_submitted_qc>July 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <keyword>Cancer</keyword>
  <keyword>elderly</keyword>
  <keyword>geriatric evaluation</keyword>
  <keyword>safety</keyword>
  <keyword>chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Digestive System Diseases</mesh_term>
    <mesh_term>Gastrointestinal Diseases</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
    <mesh_term>Prostatic Diseases</mesh_term>
    <mesh_term>Ovarian Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

